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Background: We defined the rates of and reasons for premature cessation of aspirin and/or thienopyridine therapy in pts with ST-elevation 
myocardial infarction (STEMI) in whom stents were implanted in the HORIZONS-AMI trial.
Methods: Post discharge recommendations included daily aspirin 75 to 81 mg permanently and clopidogrel 75 mg for at least 6 months (1 year or 
longer recommended). Follow-up information including occurrence of clinical events, stent thrombosis and medications was collected at 30 days, 6 
months and 1 year.
Results: Follow-up medication data in 3142 are presented in the Table. At 30-day F/U, high cost was the most frequent reason for thienopyridine 
discontinuation (61.2%), thienopyridine side effects (11.9%), physician’s instructions (10.4%) and unplanned surgery (7.5%). At 6-month F/U, the 
majority of pts had discontinued thienopyridine due to physician’s instructions (42.4%), high cost (35.7%), unplanned surgery (8.6%), side effects 
(4.1%) and other reasons (13.4%). Finally, prior to the 1-year F/U, thienopyridines had been discontinued most frequently due to physician’s 
instructions (74.5%), high cost (16.6%), unplanned surgery (2.2%), side effects (1.5%) or other reasons (7.8%).
Conclusions: The majority of pts treated with primary stenting for STEMI continued dual antiplatelet therapy at 6 months. High cost, physician’s 
instructions and unplanned surgery were the most frequent reasons of premature cessation of thienopyridine at F/U. 
Medications
Discharged patients treated with stents in HORIZONS-AMI (N=3142)
At discharge At 30 days At 6 months At 1 year
Aspirin 98.9% 98.2% 97.6% 97.2%
Thienopyridine 99.6% 98.8% 92.9% 71.4%
